Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01762046 · ClinicalTrials.gov registry record · Phase 1
Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans
A Phase 1 study of Diabetes Mellitus, Type 2, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 1,033
- Enrollment target
- 3
- Study locations
NCT01762046 is a Phase 1 study of Diabetes Mellitus, Type 2 that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 1,033 participants, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT01762046, a Phase 1 study of Diabetes Mellitus, Type 2, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,033 participants
- Enrollment target
- 3
- Study locations
Study Summary
The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect of anti-diabetic medications. In addition, physiological responses to an insulin secretagogue or an insulin sensitizer may shed light on the mechanism of action of reported genetic associations.
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Glipizide
- OTHER Oral Glucose Tolerance Test
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Joslin Diabetes Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,033 participants |
| Start Date | 2008-01 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01762046
The ClinicalTrials.gov registry entry for NCT01762046 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1,033 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,482-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (77% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 3 interventions - of which Metformin is the first listed.
NCT01762046 reports 3 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01762046 about?
NCT01762046 is a clinical study titled "Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans". The SUGAR-MGH investigators are studying the influence of inherited gene variants on the response to two commonly prescribed type 2 diabetes medications, metformin and glipizide. They hypothesize that variants in genes that are associated with type 2 diabetes or related traits may impact the effect ...
What is the current status of trial NCT01762046?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1,033 participants. The study started on 2008-01. Estimated completion is 2025-12.
What conditions does trial NCT01762046 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT01762046?
The interventions under investigation include: Metformin (DRUG), Glipizide (DRUG), Oral Glucose Tolerance Test (OTHER).
Who is sponsoring clinical trial NCT01762046?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01762046 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006)
RECRUITING · Phase 1
-
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
RECRUITING · Phase 1
-
Study of Subcutaneously Administered ENT-03 for the Treatment of Obesity and Diabetes
ACTIVE NOT RECRUITING · Phase 1
-
A Family Dyad-focused Diabetes Self-Management Intervention for African American Adults
ACTIVE NOT RECRUITING · Phase 1
-
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
COMPLETED · Phase 1
-
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.